V8 Peptides — Engineered Performance
Research Library
PT-141 Structure: Cyclic Lactam, Sequence and Mass
PT-141Chemistry

PT-141 Structure: Cyclic Lactam, Sequence and Mass

V8 Peptides Research TeamUpdated

Compiled from peer-reviewed literature and manufacturer analytical data for laboratory research reference.

Quick answer

What is the chemical structure of PT-141, and how do you check it? PT-141 (bremelanotide) is written Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH with the formula C50H68N14O10. It is a seven-position cyclic peptide: an N-acetyl cap, norleucine in place of methionine, and a lactam ring formed between the Asp side-chain carboxyl and the Lys side-chain amine, enclosing the His-D-Phe-Arg-Trp core of the melanocortin pharmacophore. The calculated average mass is about 1,025.2 Da (monoisotopic about 1,024.5 Da). Identity is checked by observed mass against these values, by HPLC retention, and by confirming that the sequence line matches the lot certificate. Supplied for laboratory research use only.

The sequence line on the V8 PT-141 page, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, packs a lot of chemistry into a few symbols. It does not read like an ordinary peptide, and readers searching for the structure are often confused by the lowercase "cyclo", the "Nle" and the "D-Phe". This article decodes each element, links each to the medicinal-chemistry papers in which the design logic was developed, and shows the arithmetic for checking the formula and mass. It covers structure only. The relationship to the receptor system is in the companion article on melanocortin receptors, the lineage is in the PT-141 and Melanotan II comparison, and the broader entry is the PT-141 research overview. For laboratory research use only.

Reading the sequence line symbol by symbol

SymbolMeaningWhy it is there
Ac-N-terminal acetyl groupCaps the amino terminus; removes a positive charge and protects against aminopeptidases
NleNorleucine, an unbranched six-carbon amino acidReplaces methionine, which is prone to oxidation, with a side chain of similar size and no sulfur
cyclo[ ... ]The residues in brackets are joined in a ringConstrains the backbone and side-chain geometry
AspAspartic acid; its side-chain carboxyl forms the ring bondSupplies the acyl partner of the lactam
His-D-Phe-Arg-TrpThe four-residue coreRecognized as the message sequence of melanocortin peptides
D-PheD-enantiomer of phenylalanineSlows proteolysis and raises potency in melanotropin analogs
LysLysine; its side-chain amine closes the ringSupplies the amine partner of the lactam
-OHFree carboxylic acid at the C-terminusDistinguishes this from amide-terminated relatives

The core His-Phe-Arg-Trp is present in alpha-melanocyte-stimulating hormone itself, and the reference structure used in the medicinal chemistry papers is Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 (Al-Obeidi et al., 1989). PT-141 retains the core and the lysine position, drops the flanking residues, and ties the ends together.

The design lineage in three steps

Step 1: stability by substitution. A 1980 study showed that heat-alkali exposure of alpha-MSH produced prolonged biological activity, traced the effect to partial racemization at positions 4 (methionine) and 7 (phenylalanine), and then synthesized [Nle4, D-Phe7]-alpha-MSH, which showed prolonged activity, resistance to degradation by serum enzymes and dramatically increased potency in frog-skin, adenylate cyclase and tyrosinase assays (Sawyer et al., 1980). That paper is the origin of the two substitutions that appear in PT-141, norleucine for methionine and D-phenylalanine for L-phenylalanine.

Step 2: shortening and cyclizing. Later work designed cyclic lactam fragment analogs of alpha-MSH, using earlier structure-activity data and theoretical studies, with the general structure Ac-[Nle4, Xxx5, D-Phe7, Yyy10]-alpha-MSH4-10-NH2, where Xxx is Glu or Asp and Yyy is Lys, Orn, Dab or Dpr, and the lactam bridge formed between the two side chains (Al-Obeidi et al., 1989). An earlier study had already reported cyclic lactam analogs of Ac-[Nle4]alpha-MSH4-11-NH2 (Sugg et al., 1988). The abstracts frame these as potent and prolonged-acting analogs.

Step 3: receptor selectivity. After the cloning of the melanocortin receptors, a further study examined cyclic lactam analogs of Ac-Nle4-cyclo[Asp5, D-Phe7, Lys10]alpha-MSH-(4-10)-NH2 and reported that bulky aromatic residues at position 7 gave high antagonist potency and selectivity at specific melanocortin receptors (Hruby et al., 1995). The lesson for readers is that small changes at the D-Phe position can change a compound from agonist to antagonist, so a one-residue discrepancy in a sequence line is not cosmetic.

Where PT-141 differs from the 1989 designs

PT-141 in the product listing is a six-residue ring plus the Nle cap, with the ring spanning Asp to Lys, and a free C-terminal acid. The lactam analogs described in the 1989 and 1995 abstracts are written as amides and include extra residues or different ring members, such as Glu, Orn, Dab or Dpr in the ring. So PT-141 belongs to the same structural family but is not identical to those compounds, and the literature should not be mixed without checking each sequence. The family relationship is accurate, and the identity of any specific numerical result is a matter of reading each paper's own compound.

Formula and mass: the arithmetic

The product page lists the molecular formula C50H68N14O10. Using standard atomic masses (C 12.011, H 1.008, N 14.007, O 15.999), the average molar mass is 50 × 12.011 + 68 × 1.008 + 14 × 14.007 + 10 × 15.999, which is about 1,025.2 g/mol. Using the monoisotopic masses of the most abundant isotopes (C 12.000, H 1.00783, N 14.00307, O 15.99491), the monoisotopic mass is about 1,024.52 Da. In electrospray mass spectrometry, the singly protonated ion is expected near m/z 1,025.5 and the doubly protonated ion near m/z 513.3, calculated by adding one or two proton masses to the monoisotopic mass and dividing by the charge. Observed values within the instrument's stated mass accuracy of these are consistent with the formula; a mass shift of 16 Da would suggest oxidation (for example of tryptophan), and a shift of 18 Da would suggest an uncyclized, ring-opened form. Those diagnostic shifts are arithmetic consequences of the structure, not findings from the cited papers.

ObservationArithmeticPossible interpretation
[M+H]+ near 1,025.51,024.52 + 1.007Consistent with intact cyclic peptide
[M+2H]2+ near 513.3(1,024.52 + 2 × 1.007) ÷ 2Same species, doubly charged
+16 Da relative to expectedOne added oxygenOxidation, for example at Trp
+18 Da relative to expectedOne added waterRing-opened (hydrolyzed) lactam
Same mass, different retentionIsomers are isobaricEpimerization, such as D-Phe racemized to L-Phe

The last row matters because the D-Phe residue is isobaric with L-Phe: mass spectrometry alone cannot show that the correct enantiomer is present. Chiral amino-acid analysis, which hydrolyzes the peptide and resolves the enantiomers, or comparison of HPLC retention with a reference of known configuration, is needed. The general method of amino-acid analysis is described in the protocols literature (Amino Acid Analysis, Current Protocols in Protein Science).

How such rings are made

The cyclic lactam analogs in the early literature were assembled on solid support. One report describes preparing two side-chain lactam analogs of the alpha-MSH 4-11 fragment on p-methylbenzhydrylamine resin using a combination of N-alpha-Boc and N-alpha-Fmoc strategies, with diphenyl phosphorazidate mediating the cyclization (Sugg et al., 1988). The underlying solid-phase approach goes back to Merrifield's synthesis of a tetrapeptide on a polymer support (Merrifield, 1963). The practical consequence for a buyer is that the ring is closed by a separate chemical step, and incomplete closure leaves a linear, ring-open species that is 18 Da heavier and is the first impurity to look for.

Checking identity in practice

  1. Match the sequence line to the lot certificate. The listing and the certificate should state the same cyclization and the same terminal groups. How to read each field is in how to read a COA, and published lots are in the COA library.
  2. Compare observed mass with 1,025.2 (average) or 1,024.52 (monoisotopic). Know which your instrument reports.
  3. Compare HPLC retention with a reference lot and read the chromatogram for shoulders, which may be epimers. The purity listing of ≥98% is a chromatographic area figure; see PT-141 purity testing and HPLC vs mass spectrometry.
  4. Record the lot. Store as the page states: refrigerate at 2–8 °C, −20 °C for long-term, protected from heat, moisture and light.

For stock concentration, the arithmetic is mass divided by molar mass divided by volume, using 1,025.2 g/mol; the calculator performs the conversion. A 10 mg vial holds about 9.75 µmol on a gross-mass basis. Net peptide content may be lower because of water and counter-ions, and the certificate is the place to look for that.

Limits of this structural reading

This article relies on the abstracts of the cited papers and on the sequence and formula on the product page. It does not reproduce NMR or crystallographic structures of PT-141. It states what the family of cyclic lactam melanotropins looks like and how the identity of a sample can be checked. It does not make statements about biological effects in animals or people. Further reading: what is PT-141, where to buy PT-141 for sourcing documentation, and the full catalog in the shop.

Frequently asked questions

What is PT-141's sequence?

The product page gives Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH: an acetylated, norleucine-containing cyclic peptide with a lactam between the Asp and Lys side chains.

What is the molecular formula and mass?

C50H68N14O10, with an average molar mass of about 1,025.2 g/mol and a monoisotopic mass of about 1,024.52 Da.

What does the lactam do?

It joins the Asp side-chain carboxyl to the Lys side-chain amine, forming a ring that constrains the structure. Cyclic lactam melanotropin analogs were designed in the late 1980s as potent and prolonged-acting compounds.

Why norleucine instead of methionine?

Norleucine has a similar side-chain size without sulfur, so it avoids methionine oxidation. The Nle4 and D-Phe7 substitutions were introduced in a 1980 alpha-MSH analog study.

Why is D-Phe important?

D-Phe7 analogs were reported to be resistant to enzymatic degradation and highly potent in melanotropin assays. Changes at this position can also convert agonists into antagonists.

Can mass spectrometry confirm the D-configuration?

No. D- and L-phenylalanine give the same mass. Chiral amino-acid analysis or HPLC comparison with a configured reference is needed.

What does a +16 Da peak suggest?

One added oxygen, for example oxidation of tryptophan. A +18 Da peak suggests a ring-opened, hydrolyzed form.

Is PT-141 the same as the compounds in the 1989 papers?

It is in the same structural family, but those compounds are mostly amides with different ring members, so each paper's compound should be read individually.

How many micromoles are in a 10 mg vial?

About 9.75 µmol on a gross-mass basis, using 1,025.2 g/mol. Correct for net peptide content if the certificate reports it.

How is it stored?

Per the product page: refrigerate at 2–8 °C, −20 °C for long-term, and protect from heat, moisture and light.

Research-use statement

All material discussed here is supplied for laboratory research use only; not for human consumption, and not a drug, food or cosmetic.

Related reading: How PT-141 Activates Melanocortin Receptors, Buying PT-141 for Research: What to Evaluate, PT-141 Structure-Activity: Nle, D-Phe and the Ring.

References

  1. Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, et al. 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity. Proc. Natl. Acad. Sci. U.S.A.. 1980;77(10):5754-5758. doi:10.1073/pnas.77.10.5754
  2. Al-Obeidi F, Castrucci AMdL, Hadley ME, Hruby VJ. Potent and prolonged-acting cyclic lactam analogs of .alpha.-melanotropin: design based on molecular dynamics. J. Med. Chem.. 1989;32(12):2555-2561. doi:10.1021/jm00132a010
  3. Sugg EE, De L. Castrucci AM, Hadley ME, Van Binst G, Hruby VJ. Cyclic lactam analogs of Ac-[Nle4].alpha.-MSH4-11-NH2. Biochemistry. 1988;27(21):8181-8188. doi:10.1021/bi00421a029
  4. Hruby VJ, Lu D, Sharma SD, de L. Castrucci A, Kesterson RA, Al-Obeidi FA, et al. Cyclic lactam .alpha.-melanotropin analogs of Ac-Nle4-cyclo[Asp5,D-Phe7,Lys10]-.alpha.-melanocyte-stimulating hormone-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. J. Med. Chem.. 1995;38(18):3454-3461. doi:10.1021/jm00018a005
  5. Rutherfurd SM, Gilani GS. Amino Acid Analysis. CP Protein Science. 2009;58(1). doi:10.1002/0471140864.ps1109s58
  6. Merrifield RB. Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide. J. Am. Chem. Soc.. 1963;85(14):2149-2154. doi:10.1021/ja00897a025

Research Use Only. All products are sold strictly for laboratory research and development purposes only. Not for human or animal consumption. Not a drug, food, or cosmetic. By purchasing, you affirm you are a qualified researcher or institution.